201 related articles for article (PubMed ID: 29122661)
1. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
2. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
3. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
4. Determination of key parameters for a mechanism-based model to predict Doxorubicin release from actively loaded liposomes.
Csuhai E; Kangarlou S; Xiang TX; Ponta A; Bummer P; Choi D; Anderson BD
J Pharm Sci; 2015 Mar; 104(3):1087-98. PubMed ID: 25561354
[TBL] [Abstract][Full Text] [Related]
5. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
6. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
8. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
[TBL] [Abstract][Full Text] [Related]
11. New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage.
Cern A; Marcus D; Tropsha A; Barenholz Y; Goldblum A
J Control Release; 2017 Apr; 252():18-27. PubMed ID: 28215669
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.
Maiti K; Bhowmick S; Jain P; Zope M; Doshi K; Rajamannar T
Anticancer Agents Med Chem; 2018; 18(4):597-609. PubMed ID: 29173186
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
14. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
Zhao Y; Alakhova DY; Kim JO; Bronich TK; Kabanov AV
J Control Release; 2013 May; 168(1):61-9. PubMed ID: 23474033
[TBL] [Abstract][Full Text] [Related]
15. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
[TBL] [Abstract][Full Text] [Related]
17. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
18. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
19. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
20. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]